27.09.2012 • News

Neurosearch to Sell Huntexil Drug to Israel's Teva

Danish biopharma company Neurosearch said on Thursday it had signed a 149 million Danish crowns ($25.7 million) deal with Israel's Teva Pharmaceutical Industries for the sale of its Huntington's drug Huntexil.

Under the deal, Neurosearch could also receive potential milestone payments with a total value of up to 55 million crowns, it said in a statement.

The agreement was conditional on Neurosearch shareholder approval as well as a number of standard conditions, it said.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Interview

Driving Transformation
Interconnected Global Chemicals Logistics

Driving Transformation

DP World is reshaping global chemical supply chains. Christene Smith of CHEManager interviews Markus Kanis, Global SVP Chemicals, on the company’s roadmap, new technologies, and the evolving demands of global trade.

Top-Feature

most read

Photo
News • Chemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.